X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Piramal Healthcare with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs TEVA PHARMA (Israel) - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PIRAMAL ENTERPRISES   TEVA PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
TEVA PHARMA
Dec-13
PIRAMAL ENTERPRISES/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs2,0952,709-   
Low Rs1,0252,353-   
Sales per share (Unadj.) Rs492.81,554.5-  
Earnings per share (Unadj.) Rs72.697.1-  
Cash flow per share (Unadj.) Rs94.7222.8-  
Dividends per share (Unadj.) Rs21.0085.01-  
Dividend yield (eoy) %1.33.4 40.1%  
Book value per share (Unadj.) Rs862.51,726.7-  
Shares outstanding (eoy) m172.56848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.21.6 194.4%   
Avg P/E ratio x21.526.1 82.5%  
P/CF ratio (eoy) x16.511.4 145.0%  
Price / Book Value ratio x1.81.5 123.4%  
Dividend payout %28.987.5 33.1%   
Avg Mkt Cap Rs m269,1942,146,042 12.5%   
No. of employees `0004.044.9 8.9%   
Total wages/salary Rs m17,9390-   
Avg. sales/employee Rs Th21,190.329,328.6 72.3%   
Avg. wages/employee Rs Th4,470.10-   
Avg. net profit/employee Rs Th3,120.01,832.1 170.3%   
INCOME DATA
Net Sales Rs m85,0371,318,175 6.5%  
Other income Rs m2,3380-   
Total revenues Rs m87,3741,318,175 6.6%   
Gross profit Rs m34,991360,983 9.7%  
Depreciation Rs m3,817106,549 3.6%   
Interest Rs m20,31025,891 78.4%   
Profit before tax Rs m13,202228,543 5.8%   
Minority Interest Rs m1,6991,038 163.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-100-150,026 0.1%   
Tax Rs m2,281-2,790 -81.8%   
Profit after tax Rs m12,52082,345 15.2%  
Gross profit margin %41.127.4 150.3%  
Effective tax rate %17.3-1.2 -1,415.3%   
Net profit margin %14.76.2 235.7%  
BALANCE SHEET DATA
Current assets Rs m87,590890,291 9.8%   
Current liabilities Rs m185,578776,409 23.9%   
Net working cap to sales %-115.28.6 -1,333.8%  
Current ratio x0.51.1 41.2%  
Inventory Days Days3191 34.2%  
Debtors Days Days4896 49.6%  
Net fixed assets Rs m108,523430,545 25.2%   
Share capital Rs m3453,245 10.6%   
"Free" reserves Rs m148,4810-   
Net worth Rs m148,8261,464,243 10.2%   
Long term debt Rs m144,957674,012 21.5%   
Total assets Rs m482,3943,012,453 16.0%  
Interest coverage x1.79.8 16.8%   
Debt to equity ratio x1.00.5 211.6%  
Sales to assets ratio x0.20.4 40.3%   
Return on assets %6.83.6 189.4%  
Return on equity %8.45.6 149.6%  
Return on capital %12.04.9 242.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m9,8510-   
CASH FLOW
From Operations Rs m-100,393210,049 -47.8%  
From Investments Rs m-24,202-74,429 32.5%  
From Financial Activity Rs m135,705-251,968 -53.9%  
Net Cashflow Rs m11,110-116,348 -9.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare PIRAMAL ENTERPRISES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare PIRAMAL ENTERPRISES With: GSK PHARMA  FRESENIUS KABI ONCO.  ALKEM LABORATORIES  FDC LTD.  LUPIN LTD  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Feb 23, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - DIVIS LABORATORIES COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS